Taking Wegovy with Antidepressants: What the Evidence Says

What official UK sources actually say about this combination

The NHS medicines guidance on semaglutide identifies a general class-level caution: because semaglutide slows how quickly the stomach empties, oral medicines taken alongside it may be absorbed at a different rate or to a different extent. This effect is most pronounced during the titration phase, when doses are still increasing. For most antidepressants taken once daily at a stable dose, this is unlikely to cause a dramatic problem — but it is a mechanism worth flagging to your prescriber rather than assuming it is irrelevant.

The Wegovy SmPC and Patient Information Leaflet (published on the electronic Medicines Compendium) do not list antidepressants as a contraindicated drug class, and no specific antidepressant is flagged as an absolute reason to withhold treatment. What the SmPC does reinforce is that the prescriber should be given a complete medicines list (including supplements and over-the-counter products) so that gastric-emptying effects can be factored in.

One misconception worth clearing up: many people assume that because some antidepressants cause weight gain, Wegovy simply cancels that effect and the two become a neutral pairing. That framing oversimplifies things. The interaction is not just about net weight; it is about pharmacokinetics, overlapping side effects, and individual response. Both belong in the same clinical conversation, not assessed separately.

Where the genuine uncertainty lies

The SURMOUNT and STEP trial programmes (including STEP 1, published in the New England Journal of Medicine) enrolled adults with obesity or overweight plus weight-related conditions. Participants taking psychiatric medication were not systematically excluded, but the trials were not designed to study antidepressant co-administration as a primary endpoint. That means robust head-to-head data on semaglutide plus specific antidepressant classes is limited.

What clinicians observe in practice is that SSRIs (selective serotonin reuptake inhibitors) are generally considered lower-risk co-prescriptions, partly because many are absorbed rapidly and are less sensitive to delayed gastric transit. SNRIs, TCAs and atypical antidepressants carry somewhat more variability. Lithium, used in bipolar disorder, has a narrow therapeutic window and any change in absorption timing is clinically significant, this warrants a conversation with a psychiatrist before Wegovy is started. MAOIs are rarely prescribed in the UK today, but if they are relevant to you, specialist review is essential.

Mood changes are also reported by some people during GLP-1 treatment. The MHRA Drug Safety Update index is the right place to check for any emerging signals; as of mid-2026 no formal contraindication has been issued for antidepressant combinations, but the regulator continues to monitor post-marketing data. If your mental health is currently unstable or recently changed, that context is essential for your prescriber to know.

Practical steps before and after starting Wegovy

Tell your prescriber about every medicine you take, including your antidepressant, its dose, and how long you have been on it. If your antidepressant was recently changed or your mental health team is actively adjusting your care, flag that too. A prescriber may want to liaise with your GP or psychiatrist before proceeding, and that is a reasonable, responsible step rather than a barrier.

Once treatment starts, the early weeks of dose escalation are the period to watch. Nausea is common with semaglutide and is also a side effect of several antidepressants, particularly SSRIs. If both are contributing, the combined effect can be more disruptive than either alone. Starting Wegovy at the lowest titration dose and moving slowly through the schedule is precisely why that graduated approach exists. For more on situations where Wegovy intersects with existing health conditions, the page on taking Wegovy with heart failure covers a similar framework of weighing evidence against individual risk, and if you have conditions such as kidney disease, the dedicated page on Wegovy and kidney disease sets out the specific considerations involved.

If you notice any significant change in mood, appetite regulation beyond what you expected, or a sense that your antidepressant feels different, speak to your prescriber or GP promptly. These are reportable and manageable; they are not reasons to stop treatment without clinical advice. You can also report unexpected effects directly to the MHRA via the Yellow Card scheme.

How suitability is decided at nume (and what happens next

At nume, every Wegovy consultation is reviewed personally by a GPhC-registered Independent Prescriber) a real clinician reads your full medication history, not an automated system. If antidepressants appear on your list, the prescriber will assess the specific drug, dose and clinical context before making a decision, and the same thorough approach applies to people who want to understand whether Wegovy is suitable when type 2 diabetes is also present. They may approve treatment, ask for additional information, or recommend you discuss with your GP first. All of those outcomes are the correct ones depending on your situation.

If you are already established on Wegovy through another provider and want to transfer, you can find out how nume handles that on the Wegovy treatment page. For a broader look at how semaglutide works and what the full treatment journey involves, the Wegovy overview covers the detail. And if you have questions about other situations that interact with Wegovy (pregnancy, for instance) the page on Wegovy and pregnancy gives the full picture. Suitability across the board is a clinical call; our prescribers are the right people to make it for your specific circumstances.